These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31484920)

  • 1. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
    Tan YC; Srivastava S; Won BM; Kanteti R; Arif Q; Husain AN; Li H; Vigneswaran WT; Pang KM; Kulkarni P; Sattler M; Vaidehi N; Mambetsariev I; Kindler HL; Wheeler DL; Salgia R
    Oncogenesis; 2019 Sep; 8(9):49. PubMed ID: 31484920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas.
    Srivastava S; Pang KM; Iida M; Nelson MS; Liu J; Nam A; Wang J; Mambetsariev I; Pillai R; Mohanty A; McDaniel N; Behal A; Kulkarni P; Wheeler DL; Salgia R
    iScience; 2020 Nov; 23(11):101692. PubMed ID: 33196021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.
    Petty A; Myshkin E; Qin H; Guo H; Miao H; Tochtrop GP; Hsieh JT; Page P; Liu L; Lindner DJ; Acharya C; MacKerell AD; Ficker E; Song J; Wang B
    PLoS One; 2012; 7(8):e42120. PubMed ID: 22916121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells.
    Lee HY; Mohammed KA; Goldberg EP; Kaye F; Najmunnisa N
    Cancer Invest; 2016 Aug; 34(7):293-304. PubMed ID: 27438907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
    Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
    Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
    Zhou Y; Sakurai H
    Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of EphA2 in ADAM17- and ionizing radiation-enhanced lung cancer cell migration.
    Waller V; Tschanz F; Winkler R; Pruschy M
    Front Oncol; 2023; 13():1117326. PubMed ID: 36998455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
    Nasreen N; Mohammed KA; Antony VB
    Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
    Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
    Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
    Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
    Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
    Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Fukuchi M; Nakajima M; Kuwano H
    Int J Cancer; 2003 Feb; 103(5):657-63. PubMed ID: 12494475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
    Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
    Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner.
    Graves PR; Din SU; Ashamalla M; Ashamalla H; Gilbert TSK; Graves LM
    Int J Radiat Biol; 2017 Sep; 93(9):929-936. PubMed ID: 28705041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma.
    Syed N; Barbhuiya MA; Pinto SM; Nirujogi RS; Renuse S; Datta KK; Khan AA; Srikumar K; Prasad TS; Kumar MV; Kumar RV; Chatterjee A; Pandey A; Gowda H
    Proteomics; 2015 Jan; 15(2-3):374-82. PubMed ID: 25366905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
    Zhou Y; Yamada N; Tanaka T; Hori T; Yokoyama S; Hayakawa Y; Yano S; Fukuoka J; Koizumi K; Saiki I; Sakurai H
    Nat Commun; 2015 Jul; 6():7679. PubMed ID: 26158630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.